BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 31857725)

  • 1. Development of PancRISK, a urine biomarker-based risk score for stratified screening of pancreatic cancer patients.
    Blyuss O; Zaikin A; Cherepanova V; Munblit D; Kiseleva EM; Prytomanova OM; Duffy SW; Crnogorac-Jurcevic T
    Br J Cancer; 2020 Mar; 122(5):692-696. PubMed ID: 31857725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A combination of urinary biomarker panel and PancRISK score for earlier detection of pancreatic cancer: A case-control study.
    Debernardi S; O'Brien H; Algahmdi AS; Malats N; Stewart GD; Plješa-Ercegovac M; Costello E; Greenhalf W; Saad A; Roberts R; Ney A; Pereira SP; Kocher HM; Duffy S; Blyuss O; Crnogorac-Jurcevic T
    PLoS Med; 2020 Dec; 17(12):e1003489. PubMed ID: 33301466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a Three-Biomarker Panel in Urine for Early Detection of Pancreatic Adenocarcinoma.
    Radon TP; Massat NJ; Jones R; Alrawashdeh W; Dumartin L; Ennis D; Duffy SW; Kocher HM; Pereira SP; Guarner posthumous L; Murta-Nascimento C; Real FX; Malats N; Neoptolemos J; Costello E; Greenhalf W; Lemoine NR; Crnogorac-Jurcevic T
    Clin Cancer Res; 2015 Aug; 21(15):3512-21. PubMed ID: 26240291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urine biomarkers enable pancreatic cancer detection up to 2 years before diagnosis.
    Debernardi S; Blyuss O; Rycyk D; Srivastava K; Jeon CY; Cai H; Cai Q; Shu XO; Crnogorac-Jurcevic T
    Int J Cancer; 2023 Feb; 152(4):769-780. PubMed ID: 36093581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9.
    Makawita S; Dimitromanolakis A; Soosaipillai A; Soleas I; Chan A; Gallinger S; Haun RS; Blasutig IM; Diamandis EP
    BMC Cancer; 2013 Sep; 13():404. PubMed ID: 24007603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis.
    Mayerle J; Kalthoff H; Reszka R; Kamlage B; Peter E; Schniewind B; González Maldonado S; Pilarsky C; Heidecke CD; Schatz P; Distler M; Scheiber JA; Mahajan UM; Weiss FU; Grützmann R; Lerch MM
    Gut; 2018 Jan; 67(1):128-137. PubMed ID: 28108468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nano-biotinylated liposome-based immunoassay for the ultrasensitive detection of protein biomarker in urine.
    Liu P; Fang X; Cao H; Gu M; Kong J; Deng A
    Talanta; 2018 Mar; 179():472-477. PubMed ID: 29310262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Plasma Biomarker Panel to Identify Surgically Resectable Early-Stage Pancreatic Cancer.
    Balasenthil S; Huang Y; Liu S; Marsh T; Chen J; Stass SA; KuKuruga D; Brand R; Chen N; Frazier ML; Jack Lee J; Srivastava S; Sen S; McNeill Killary A
    J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 28376184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease.
    Shaw VE; Lane B; Jenkinson C; Cox T; Greenhalf W; Halloran CM; Tang J; Sutton R; Neoptolemos JP; Costello E
    Mol Cancer; 2014 May; 13():114. PubMed ID: 24884871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A unique urinary metabolomic signature for the detection of pancreatic ductal adenocarcinoma.
    Sahni S; Pandya AR; Hadden WJ; Nahm CB; Maloney S; Cook V; Toft JA; Wilkinson-White L; Gill AJ; Samra JS; Dona A; Mittal A
    Int J Cancer; 2021 Mar; 148(6):1508-1518. PubMed ID: 33128797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urine metallomics signature as an indicator of pancreatic cancer.
    Schilling K; Larner F; Saad A; Roberts R; Kocher HM; Blyuss O; Halliday AN; Crnogorac-Jurcevic T
    Metallomics; 2020 May; 12(5):752-757. PubMed ID: 32211672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Performance of candidate urinary biomarkers for pancreatic cancer - Correlation with pancreatic cyst malignant progression?
    Yip-Schneider MT; Soufi M; Carr RA; Flick KF; Wu H; Colgate CL; Schmidt CM
    Am J Surg; 2020 Mar; 219(3):492-495. PubMed ID: 31554598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Noninvasive Diagnosis of Pancreatic Cancer Through Detection of Volatile Organic Compounds in Urine.
    Arasaradnam RP; Wicaksono A; O'Brien H; Kocher HM; Covington JA; Crnogorac-Jurcevic T
    Gastroenterology; 2018 Feb; 154(3):485-487.e1. PubMed ID: 29129714
    [No Abstract]   [Full Text] [Related]  

  • 14. Pancreatic ductal adenocarcinoma is associated with a distinct urinary metabolomic signature.
    Davis VW; Schiller DE; Eurich D; Bathe OF; Sawyer MB
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S415-23. PubMed ID: 23096698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum biomarker panels for the detection of pancreatic cancer.
    Brand RE; Nolen BM; Zeh HJ; Allen PJ; Eloubeidi MA; Goldberg M; Elton E; Arnoletti JP; Christein JD; Vickers SM; Langmead CJ; Landsittel DP; Whitcomb DC; Grizzle WE; Lokshin AE
    Clin Cancer Res; 2011 Feb; 17(4):805-16. PubMed ID: 21325298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer.
    Dong D; Jia L; Zhang L; Ma N; Zhang A; Zhou Y; Ren L
    Cancer Sci; 2018 Sep; 109(9):2841-2851. PubMed ID: 29945294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inflammatory cytokines and combined biomarker panels in pancreatic ductal adenocarcinoma: Enhancing diagnostic accuracy.
    Kruger D; Yako YY; Devar J; Lahoud N; Smith M
    PLoS One; 2019; 14(8):e0221169. PubMed ID: 31415645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of serum parameters panels for the early detection of pancreatic cancer.
    Zhang P; Zou M; Wen X; Gu F; Li J; Liu G; Dong J; Deng X; Gao J; Li X; Jia X; Dong Z; Chen L; Wang Y; Tian Y
    Int J Cancer; 2014 Jun; 134(11):2646-55. PubMed ID: 24615168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urinary metabolite prognostic biomarker panel for pancreatic ductal adenocarcinomas.
    Hipperson L; Hadden WJ; Nahm CB; Gill AJ; Samra JS; Dona A; Mittal A; Sahni S
    Biochim Biophys Acta Gen Subj; 2021 Nov; 1865(11):129966. PubMed ID: 34329704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. THBS2/CA19-9 Detecting Pancreatic Ductal Adenocarcinoma at Diagnosis Underperforms in Prediagnostic Detection: Implications for Biomarker Advancement.
    Udgata S; Takenaka N; Bamlet WR; Oberg AL; Yee SS; Carpenter EL; Herman D; Kim J; Petersen GM; Zaret KS
    Cancer Prev Res (Phila); 2021 Feb; 14(2):223-232. PubMed ID: 33067248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.